Sutro Biopharma Statistics

Total Valuation

Sutro Biopharma has a market cap or net worth of $73.73 million. The enterprise value is -$76.21 million.

Market Cap	73.73M
Enterprise Value	-76.21M

Important Dates

The last earnings date was Thursday, November 6, 2025, after market close.

Earnings Date	Nov 6, 2025
Ex-Dividend Date	n/a

Share Statistics

Sutro Biopharma has 8.51 million shares outstanding. The number of shares has increased by 17.26% in one year.

Current Share Class	8.51M
Shares Outstanding	8.51M
Shares Change (YoY)	+17.26%
Shares Change (QoQ)	+0.34%
Owned by Insiders (%)	1.67%
Owned by Institutions (%)	42.98%
Float	6.10M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.69
Forward PS	1.75
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.53

Current Ratio	2.53
Quick Ratio	2.39
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-3.53

Financial Efficiency

Return on equity (ROE) is -1,810.01% and return on invested capital (ROIC) is -256.77%.

Return on Equity (ROE)	-1,810.01%
Return on Assets (ROA)	-25.80%
Return on Invested Capital (ROIC)	-256.77%
Return on Capital Employed (ROCE)	-99.12%
Revenue Per Employee	$340,794
Profits Per Employee	-$699,248
Employee Count	310
Asset Turnover	0.32
Inventory Turnover	n/a

Taxes

In the past 12 months, Sutro Biopharma has paid $2.34 million in taxes.

Income Tax	2.34M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -69.51% in the last 52 weeks. The beta is 1.62, so Sutro Biopharma's price volatility has been higher than the market average.

Beta (5Y)	1.62
52-Week Price Change	-69.51%
50-Day Moving Average	9.26
200-Day Moving Average	9.03
Relative Strength Index (RSI)	48.18
Average Volume (20 Days)	108,553

Short Selling Information

The latest short interest is 3.52 million, so 41.36% of the outstanding shares have been sold short.

Short Interest	3.52M
Short Previous Month	3.39M
Short % of Shares Out	41.36%
Short % of Float	57.71%
Short Ratio (days to cover)	2.37

Income Statement

In the last 12 months, Sutro Biopharma had revenue of $105.65 million and -$216.77 million in losses. Loss per share was -$25.88.

Revenue	105.65M
Gross Profit	144.37M
Operating Income	-136.55M
Pretax Income	-214.42M
Net Income	-216.77M
EBITDA	-128.99M
EBIT	-136.55M
Loss Per Share	-$25.88

Full Income Statement

Balance Sheet

The company has $167.59 million in cash and $17.66 million in debt, giving a net cash position of $149.93 million or $17.61 per share.

Cash & Cash Equivalents	167.59M
Total Debt	17.66M
Net Cash	149.93M
Net Cash Per Share	$17.61
Equity (Book Value)	-87.27M
Book Value Per Share	-10.25
Working Capital	110.22M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$222.53 million and capital expenditures -$2.58 million, giving a free cash flow of -$225.11 million.

Operating Cash Flow	-222.53M
Capital Expenditures	-2.58M
Free Cash Flow	-225.11M
FCF Per Share	-$26.44

Full Cash Flow Statement

Margins

Gross margin is 136.66%, with operating and profit margins of -129.26% and -205.18%.

Gross Margin	136.66%
Operating Margin	-129.26%
Pretax Margin	-202.96%
Profit Margin	-205.18%
EBITDA Margin	-122.09%
EBIT Margin	-129.26%
FCF Margin	n/a

Dividends & Yields

Sutro Biopharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-17.26%
Shareholder Yield	-17.26%
Earnings Yield	-294.01%
FCF Yield	-305.33%

Analyst Forecast

The average price target for Sutro Biopharma is $19.67, which is 127.14% higher than the current price. The consensus rating is "Hold".

Price Target	$19.67
Price Target Difference	127.14%
Analyst Consensus	Hold
Analyst Count	7
Revenue Growth Forecast (5Y)	-2.08%
EPS Growth Forecast (5Y)	-57.54%

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on December 3, 2025. It was a reverse split with a ratio of 1:10.

Last Split Date	Dec 3, 2025
Split Type	Reverse
Split Ratio	1:10

Scores

Sutro Biopharma has an Altman Z-Score of -6.97 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-6.97
Piotroski F-Score	1